This is a published notice on the Find a Tender service: <u>https://www.find-tender.service.gov.uk/Notice/033950-2024</u>

#### Tender

## NP35925 Cardiovascular & Respiratory Medicines

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

F02: Contract notice Notice identifier: 2024/S 000-033950 Procurement identifier (OCID): ocds-h6vhtk-04afa6 Published 21 October 2024, 2:00pm

## Section I: Contracting authority

## I.1) Name and addresses

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

1 South Gyle Crescent

Edinburgh

EH12 9EB

Email

marta.siwek@nhs.scot

## Telephone

+44 07483141961

## Country

United Kingdom

#### NUTS code

UKM - Scotland

#### Internet address(es)

Main address

http://www.nss.nhs.scot/browse/procurement-and-logistics

Buyer's address

https://www.publiccontractsscotland.gov.uk/search/Search\_AuthProfile.aspx?ID=AA1188 3

## I.2) Information about joint procurement

The contract is awarded by a central purchasing body

## I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html

## I.4) Type of the contracting authority

Body governed by public law

## I.5) Main activity

Health

## Section II: Object

## II.1) Scope of the procurement

## II.1.1) Title

NP35925 Cardiovascular & Respiratory Medicines

## II.1.2) Main CPV code

• 33600000 - Pharmaceutical products

## II.1.3) Type of contract

Supplies

## II.1.4) Short description

This Framework Agreement is for the supply of Cardiovascular & Respiratory Medicines to health boards across NHS Scotland. The Goods have been split into nineteen (19) categories, each of which is identified as a "Lot". Full details of each Lot is contained in section II.2 of this notice.

## II.1.5) Estimated total value

Value excluding VAT: £95,148,458

## II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

## **II.2) Description**

## II.2.1) Title

Epoprostenol Powder and Solvent (pH 10.5) for Solution for Infusion Vials

Lot No

1

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

#### II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

#### II.2.4) Description of the procurement

Supply of Epoprostenol 500mcg and 1.5mg powder and solvent (pH10.5) for solution for infusion vials to NHS Scotland. The Authority intends awarding a multi-supplier unranked framework agreement for the Lot and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

#### II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

#### II.2.6) Estimated value

Value excluding VAT: £100,000

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

## II.2.10) Information about variants

Variants will be accepted: No

### II.2.11) Information about options

Options: No

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

#### II.2.1) Title

Epoprostenol Powder and Solvent (pH 12) for Solution for Infusion Vials

Lot No

2

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

#### II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

#### II.2.4) Description of the procurement

Supply of Epoprostenol 500mcg and 1.5mg powder and solvent (pH12) for solution for infusion vials to NHS Scotland. The Authority intends awarding a multi-supplier unranked framework agreement for the Lot and it is envisaged a maximum of 6 Framework

Participants will be awarded. Full details can be found within the ITT.

## II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

### II.2.6) Estimated value

Value excluding VAT: £4,541,953

#### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

#### II.2.10) Information about variants

Variants will be accepted: No

## II.2.11) Information about options

Options: No

#### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## II.2) Description

II.2.1) Title

Epinephrine (Adrenaline) Pre-Filled Syringes

Lot No

3

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

## II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

## II.2.4) Description of the procurement

Supply of Epinephrine (Adrenaline) Pre-filled syringes to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

## II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

## II.2.6) Estimated value

Value excluding VAT: £1,555,316

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

## II.2.10) Information about variants

Variants will be accepted: No

## II.2.11) Information about options

Options: No

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

## II.2.1) Title

Epinephrine (Adrenaline) Auto Injector Devices

Lot No

4

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

## II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working)

Scotland Act 2014.

## II.2.4) Description of the procurement

Supply of Epinephrine (Adrenaline) Auto Injector Devices to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

#### II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

#### II.2.6) Estimated value

Value excluding VAT: £813,471

#### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

#### II.2.10) Information about variants

Variants will be accepted: No

#### II.2.11) Information about options

Options: No

#### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

II.2.1) Title

**Enoxaparin Sodium Injection** 

Lot No

5

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

## II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

## II.2.4) Description of the procurement

Supply of Enoxaparin Sodium Injection to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

## II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

## II.2.6) Estimated value

Value excluding VAT: £15,288,661

### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

#### II.2.10) Information about variants

Variants will be accepted: No

#### II.2.11) Information about options

**Options: No** 

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

II.2.1) Title

**Urokinase Injections** 

Lot No

6

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

## II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

#### II.2.4) Description of the procurement

Supply of Urokinase Injections to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

#### II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

#### II.2.6) Estimated value

Value excluding VAT: £472,523

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

#### II.2.10) Information about variants

Variants will be accepted: No

## II.2.11) Information about options

Options: No

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

## II.2.1) Title

Isosorbide Mononitrate Modified-Release (M/R) Capsules and Tablets

Lot No

7

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

## II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

## II.2.4) Description of the procurement

Supply of Isosorbide Mononitrate Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

#### II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

### II.2.6) Estimated value

Value excluding VAT: £191,878

#### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

#### II.2.10) Information about variants

Variants will be accepted: No

#### II.2.11) Information about options

Options: No

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

II.2.1) Title

Diltiazem Hydrochloride Modified-Release (M/R) Capsules and Tablets

Lot No

8

### II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

#### II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

#### II.2.4) Description of the procurement

Supply of Diltiazem Hydrochloride Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

#### II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

## II.2.6) Estimated value

Value excluding VAT: £119,355

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

## II.2.10) Information about variants

Variants will be accepted: No

## II.2.11) Information about options

Options: No

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

## II.2.1) Title

Verapamil Hydrochloride Modified-Release (M/R) Capsules and Tablets

Lot No

9

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

## II.2.3) Place of performance

NUTS codes

UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working)

Scotland Act 2014.

## II.2.4) Description of the procurement

Supply of Verapamil Hydrochloride Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

## II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

## II.2.6) Estimated value

Value excluding VAT: £62,465

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

## II.2.10) Information about variants

Variants will be accepted: No

## II.2.11) Information about options

Options: No

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## II.2) Description

#### II.2.1) Title

Nifedipine Modified-Release (M/R) Capsules and Tablets

Lot No

10

#### II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

#### II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

#### II.2.4) Description of the procurement

Supply of Nifedipine Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

#### II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

#### II.2.6) Estimated value

Value excluding VAT: £136,569

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

## II.2.10) Information about variants

Variants will be accepted: No

## II.2.11) Information about options

Options: No

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

## II.2.1) Title

Theophylline Modified-Release (M/R) Capsules and Tablets

Lot No

11

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

#### II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

#### II.2.4) Description of the procurement

Supply of Theophylline Modified Release Capsules and Tablets to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

#### II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

#### II.2.6) Estimated value

Value excluding VAT: £32,341

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

## II.2.10) Information about variants

Variants will be accepted: No

## II.2.11) Information about options

Options: No

### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

#### II.2.1) Title

Branded and Branded Generic Inhalers

Lot No

12

#### II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

#### II.2.3) Place of performance

NUTS codes

UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

#### II.2.4) Description of the procurement

Supply of Branded and Branded Generic Inhalers to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi-supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

#### II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

#### II.2.6) Estimated value

Value excluding VAT: £4,897,823

#### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

#### II.2.10) Information about variants

Variants will be accepted: No

#### II.2.11) Information about options

Options: No

#### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

II.2.1) Title

**Iloprost Medicines** 

Lot No

13

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

### II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

#### II.2.4) Description of the procurement

Supply of Iloprost Solutions for Infusion and Nebuliser solutions to NHS Scotland in a range of presentations. The Authority intends awarding each product line as a multi supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

#### II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

## II.2.6) Estimated value

Value excluding VAT: £1,572,128

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

## II.2.10) Information about variants

Variants will be accepted: No

## II.2.11) Information about options

Options: No

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

## II.2.1) Title

**Dalteparin Injections** 

Lot No

14

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

## II.2.3) Place of performance

NUTS codes

UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working)

Scotland Act 2014.

### II.2.4) Description of the procurement

Supply of Dalteparin Injection to NHS Scotland in a range of presentations. The Authority intends awarding a multi supplier unranked framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded per line. Full details can be found within the ITT.

#### II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

#### II.2.6) Estimated value

Value excluding VAT: £17,380,231

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

#### II.2.10) Information about variants

Variants will be accepted: No

#### II.2.11) Information about options

Options: No

#### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

II.2.1) Title

**Tinzaparin Sodium Injections** 

Lot No

15

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

## II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

## II.2.4) Description of the procurement

Supply of Tinzaparin Sodium Injection to NHS Scotland in a range of presentations. The Authority intends awarding a multi supplier unranked framework agreement on a lot basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

## II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

## II.2.6) Estimated value

Value excluding VAT: £836,630

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

#### II.2.10) Information about variants

Variants will be accepted: No

#### II.2.11) Information about options

Options: No

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

II.2.1) Title

Icatibant Solution for Injection

Lot No

16

#### II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

#### II.2.4) Description of the procurement

Supply of Icatibant Solution for Injection to NHS Scotland. The Authority intends awarding a multi supplier ranked Framework Agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded per line. Full details can be found within the ITT.

#### II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

#### II.2.6) Estimated value

Value excluding VAT: £381,184

#### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

#### II.2.10) Information about variants

Variants will be accepted: No

## II.2.11) Information about options

Options: No

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

II.2.1) Title

**Treprostinil Injection** 

Lot No

17

#### II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

#### II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

## II.2.4) Description of the procurement

Supply of Treprostinil Injection to NHS Scotland in a range of presentations. The Authority intends awarding an unranked multi supplier framework agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded. Full details can be found within the ITT.

## II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

### II.2.6) Estimated value

Value excluding VAT: £283,678

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

#### II.2.10) Information about variants

Variants will be accepted: No

## II.2.11) Information about options

**Options: No** 

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

II.2.1) Title

Direct Acting Oral Anticoagulants (DOACs)

Lot No

#### 18

#### II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

#### II.2.3) Place of performance

NUTS codes

• UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

#### **II.2.4)** Description of the procurement

Supply of Direct Acting Oral Anticoagulants (DOACs) to NHS Scotland in a range of presentations. The Authority intends awarding a multi supplier ranked Framework Agreement on a line by line basis and it is envisaged a maximum of 6 Framework Participants will be awarded per line. Full details can be found within the ITT.

#### II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

#### II.2.6) Estimated value

Value excluding VAT: £12,053,015

#### II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

### II.2.10) Information about variants

Variants will be accepted: No

#### II.2.11) Information about options

Options: No

## II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

#### II.2.1) Title

All Other Cardiovascular & Respiratory Medicines

Lot No

19

## II.2.2) Additional CPV code(s)

• 33600000 - Pharmaceutical products

#### II.2.3) Place of performance

NUTS codes

UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

#### **II.2.4)** Description of the procurement

Supply of All Other Cardiovascular & Respiratory Medicines to NHS Scotland in a range of presentations. Each product line will be treated as an individual Lot. The Authority intends awarding each product line to a single Framework Participant. Full details can be found within the ITT.

## II.2.5) Award criteria

Quality criterion - Name: Logistics / Weighting: 5

Price - Weighting: 95

#### II.2.6) Estimated value

Value excluding VAT: £34,429,229

## II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

Yes

Description of renewals

This framework includes the option(s) to extend for period(s) up to a total period of twentyfour (24) months upon giving not less than three (3) months written notice of each extension, such notice to expire no later than the date the Framework Agreement is due to expire.

#### II.2.10) Information about variants

Variants will be accepted: No

#### II.2.11) Information about options

Options: No

#### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

## Section III. Legal, economic, financial and technical information

## III.1) Conditions for participation

# III.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions

Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015.

#### III.1.3) Technical and professional ability

List and brief description of selection criteria

(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL,PLGB or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender.

(b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent at the date of submission of the tender.

(c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design.

(d) Potential Framework Participants are required to provide evidence that their organisation has taken steps to build their awareness of the climate change emergency and how they will respond.

Minimum level(s) of standards possibly required

(a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender, should be included in the Qualification Envelope of the ITT under the Technical and Professional ability: Quality Control.

(b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent at the date of submission of the tender should be included in the Qualification Envelope of the ITT under the Quality Assurance Schemes.

(c) Confirmation that samples for tendered Goods will be supplied upon request to ensure

compliance with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design. Confirmation of sample provision should be provided in the Qualification Envelope of the ITT under Technical and Professional ability: Products

(d) A completed copy of the Bidder Climate Change Plan Template, including planned projects and actions to reduce the bidder's carbon emissions should be provided in the Qualification Envelope of the ITT under Environmental Management Criteria. This does not need to contain calculated carbon emissions.

## **Section IV. Procedure**

## **IV.1)** Description

## IV.1.1) Type of procedure

Open procedure

## IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

## IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

## **IV.2) Administrative information**

## IV.2.2) Time limit for receipt of tenders or requests to participate

Date

20 November 2024

Local time

12:00pm

## IV.2.4) Languages in which tenders or requests to participate may be submitted

English

#### IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 3 (from the date stated for receipt of tender)

#### IV.2.7) Conditions for opening of tenders

Date

20 November 2024

Local time

12:00pm

## Section VI. Complementary information

## VI.1) Information about recurrence

This is a recurrent procurement: No

## VI.2) Information about electronic workflows

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

## VI.3) Additional information

The estimated value(s) referred to in Section II.1.5 and within all Lots cover(s) the thirty six (36) month contract duration and the twenty four (24) month extension period of the framework agreement.

The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 27594. For more information see: <u>http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343</u>

A sub-contract clause has been included in this contract. For more information see: <u>http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2363</u>

Community benefits are included in this requirement. For more information see: <u>https://www.gov.scot/policies/public-sector-procurement/community-benefits-in-</u>

#### procurement/

A summary of the expected community benefits has been provided as follows:

It is a mandatory requirement that potential framework participants/contractors agree to support the concept, provision, and ongoing development of community benefits provision in relation to this framework/contract.

Potential framework participants/contractors are required to agree to this mandatory requirement. They are also requested to provide a summary of the community benefits that have recently been delivered within Scotland, if at all, and what impact and outcomes these have achieved.

Potential framework participants/contractors are required to summarise any proposed community benefits that will be developed and delivered as part of this framework/contract if successful or, alternatively, potential framework participants/contractors confirm that they will engage with the NHS Scotland's Community Benefits Gateway (CBG). This gateway, developed through requests from suppliers seeking opportunities to support the delivery of community benefits within the contracting region, provides information on community benefit opportunities. The CBG is a free and easy to use online service that connects NHS Scotland suppliers with third sector community organisations within Scotland and will be used for tracking and reporting and is an approved compliant route to the realisation of community benefits.

For further information please visit NHSS Community Benefit Gateway (<u>https://www.nss.nhs.scot/procurement-and-logistics/sustainability/access-our-community-benefit-gateway/</u>).

(SC Ref:777704)

#### VI.4) Procedures for review

VI.4.1) Review body

Sheriff Court House

27 Chambers Street

Edinburgh

EH1 1LB

Email

#### edinburgh@scotcourts.gov.uk

Country

United Kingdom

Internet address

https://www.scotcourts.gov.uk/the-courts/court-locations/edinburgh-sheriff-court-and-justice-of-the-peace-court

#### VI.4.3) Review procedure

Precise information on deadline(s) for review procedures

The Authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic operators was unsuccessful. The notification will incorporate a 'standstill period' of a

minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which

the Authority dispatches the notice(s) and the date on which the Authority proposes to conclude the relevant framework agreement. The bringing of court proceedings against the Authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued, or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer(s). The bringing of court proceedings against the

Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.